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Letters to the Editor
Masked Hypertension and
White-Coat Hypertension Prognosis
The recent published study by Ohkubo et al. (1) investigated the
interesting relationship between masked hypertension and the risk
of cardiovascular mortality and morbidity in the future. This
10-year follow-up study demonstrated that the relative hazards of
masked hypertensive patients and sustained hypertensive patients
were significantly higher than the hazards for white-coat hyper-
tensive patients and patients with normal blood pressure (BP).
However, there are some limitations that deserve special atten-
tion. The BP level may have been decreased coincidently during
the single-office BP measurement owing to BP variability. In
addition, one-third of the subjects classified as masked hyperten-
sive received antihypertensive treatment and may have taken their
medication a few hours before the visit, leading to decreased BP
levels at the time of measurement. When these drugs have a short
half-life and/or patients have a poor adherence to the prescribed
medication, BP may be higher outside the office, causing a
classification of masked hypertension.
Thus, this indicates that the subjects who are classified as
masked hypertensive are in fact true hypertensives, as is confirmed
by their ambulatory BP value, which is considered to be more
reliable than conventional office BP measurements (2).
Although no statistical difference was given between relative
hazards for sustained and masked hypertension, a potential reason
that subjects classified as masked hypertensive had a lower risk of
cardiovascular morbidity than did those classified as sustained
hypertensive may be explained by the fact that the chance of being
classified as masked hypertensive is higher for mild to moderate
hypertensive patients than it is for severe hypertensive patients
because their BP values are closer to the upper limits.
Therefore, we conclude that masked hypertension is an errone-
ous description of sustained hypertension.
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REPLY
We appreciate the comments by Verberk and colleagues regarding
our recent study (1). We agree with their comments that blood
pressure (BP) level may have been decreased coincidently at the
single-office BP measurement occasion due to BP variability. That
is exactly the nature of “casual” office BP.
As Verberk and colleagues correctly pointed out, one-third of
our study subjects who were classified as masked hypertension
received antihypertensive treatment (1). Baseline proportion of
those with antihypertensive treatment was higher in subjects with
masked hypertension than in those with sustained normal BP (1).
Antihypertensive treatment is an established cause of masked
hypertension, especially when office BP is measured a few hours
after antihypertensive drugs are taken (2). The use of two or more
antihypertensive drugs also increases the odds of masked hyper-
tension compared with the monotherapy in treated hypertensive
patients (3).
As well as subjects with sustained hypertension, those who are
classified as masked hypertension are in fact “true” hypertensives in
terms of their cardiovascular risks. There was no significant
difference between relative hazards for sustained and masked
hypertension (p  0.3 for all primary and secondary outcomes).
The most important factor is that masked hypertension may not be
identified by “casual” office BP measurement, which is usually
“causal” in the worst sense of the word (4). Use of ambulatory BP
monitoring or self-measured home BP can identify masked hyper-
tension. Physicians/health practitioners should recognize at least
the possibility that office BP measurements would miss masked
hypertension. Nevertheless, they do not take into account the
possibility of masked hypertension should the patients develop
organ damage/cardiovascular diseases despite good control of office
BP and other risk factors. If these patients are not identified and do
not receive appropriate treatment, they could develop further organ
damage/cardiovascular diseases.
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Training in Cardiology Fellowship Programs
The study by Gurvitz et al. (1) provides a measured and
reasonable assessment of the workforce of cardiologists to care
for adult patients with congenital heart disease (CHD), the
exposure of adult and pediatric cardiology fellows to adult
patients with CHD, and several excellent suggestions to aug-
ment the workforce.
The recommended training for physicians who care for adult
patients with CHD has been influenced by, 1) the approach to the
patient population, and 2) the perspective of the individual or
group making training recommendations.
In regard to the approach to the patient population, care of
patients can be dictated by 1) the age of the patient, or 2) by the
patient’s disease. In most situations, patient care is divided by age.
Internists and family physicians care for adults, and pediatricians
care for infants, children, and adolescents. This paradigm makes
sense for diseases that are unique to different age groups.
However, it may not make sense to use this paradigm if one
group of physicians inherently is better trained to care for the
specific disease than is another group of physicians. For diseases
that occur in all age groups, what is important is whether or not
the physician is skilled to treat the specific disease; not whether
the physician is trained to care for children or adults. The
management of CHD is taught in pediatric cardiology training
programs. Thus, in the case of patients with CHD, physicians
trained in pediatric cardiology are most appropriately trained to
take care of these patients regardless of the patient’s age. Of
course, the pediatric cardiologist should work in conjunction
with the patient’s primary care internist, family practitioner, or
internist cardiologist.
Regarding the perspective of the individual or group making
training recommendations, several attempts have been made to
define appropriate training for physicians who care for adult
patients with CHD. The perspective primarily has been from the
viewpoint of training internal medicine cardiologists. This is
understandable because in most internal medicine cardiology
training programs, there is minimal exposure to CHD. Relatively
few, if any, graduates of internal medicine cardiology training
programs are trained to treat patients with CHD. For these
physicians, one or more years of training in CHD, beyond
standard fellowship, is essential.
This contrasts with training of pediatric cardiologists, who
are fully trained to care for patients with CHD during standard
(three year) fellowship. Pediatric cardiologists need not (and
perhaps should not) be the primary care physician for adult
patients with CHD but certainly can function as their CHD
cardiologist.
The anticipated shortage of physicians trained to treat adults
with CHD may, in fact, be much less when the contributions of
pediatric cardiologists to the care of these patients are recognized.
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We appreciate the interest Dr. Driscoll expresses in our study (1). In
his letter, Dr. Driscoll suggests that pediatric cardiologists are better
equipped to treat adult congenital heart disease (CHD) patients
because they are “inherently better trained” in the underlying diseases,
and that they should “work in conjunction with the patient’s primary
care internist, family practitioner, or internist cardiologist.” There is
no reasonable dispute with this premise as pediatric cardiologists often
receive more training in the underlying diseases at issue. We respect-
fully disagree, however, with Dr. Driscoll’s conclusion that care for an
emerging population of adult CHD patients should be committed
solely, or primarily, to pediatric cardiologists.
Instead, several considerations favor the conclusion that adult
and dual-boarded cardiologists should be properly trained to take
an increasingly significant role in the care of adult CHD patients.
1. The numbers favor a greater and necessary role for adult
cardiologists. As noted in our study, we estimate that the
number of adult CHD patients is growing relatively quickly.
Adult cardiologists in the U. S. outnumber pediatric cardiol-
ogists by a factor of 10 to 15 (1). A strategy that relies on
pediatric cardiologists to treat new and existing pediatric
patients as well as adult CHD patients will worsen the ratio of
patients to cardiologists.
2. Adult CHD patients have other adult-onset medical issues.
The CHD requires management in conjunction with acquired
conditions of adulthood, including pregnancy, acquired heart
disease, and other adult diseases such as diabetes and cancers.
Adult cardiologists are better trained to deal with these
acquired medical issues in which pediatric cardiologists have
little or no training.
3. Practical difficulties accompany adult CHD inpatients. Chil-
dren’s hospitals often cannot admit adult patients, and pedi-
atric cardiologists may not be able to obtain admitting privi-
leges at adult-care facilities.
Ultimately, the argument is not about which group should
contribute more care for adult CHD patients. The question is how
we can supply the needed care to this growing population given a
potential provider shortage, coupled with shortages in training of
most adult and pediatric cardiologists. As mentioned in our study,
this care will currently need to be provided in a number of different
combinations and arrangements. Our assessment is that pediatric
cardiologists, adult cardiologists, congenital cardiac surgeons, and
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